"It’s exciting to be developing a novel technology that can truly make a difference in the lives of individuals suffering from genetic disorders."
Kevin Chow has over two decades of experience leading business development and corporate strategy in both large and small biopharmaceutical companies. Dr. Chow was most recently Co-founder, President and CEO of Vitaeris (acquired by CSL Behring in June 2020), a privately held biotechnology company conducting a multi-national Phase 3 study in kidney transplant rejection. Under Dr. Chow’s leadership, Vitaeris repurposed the anti-IL6 mAb clazakizumab from rheumatoid arthritis into the field of solid organ transplantation under an unprecedented FDA Subpart E accelerated approval pathway in the field of transplant. Prior to co-founding Vitaeris in early 2016, Dr. Chow served as Head of Business Development at Alder Biopharmaceuticals, where he led partnering efforts for Alder’s monoclonal antibody pipeline. Previously, Dr. Chow led pulmonary in-licensing at Gilead Sciences and also helped manage the integration of Corus Pharma after its acquisition by Gilead in 2006. Prior to Gilead, Dr. Chow served as Director of Business Development for Corus Pharma, a specialty pharmaceutical company focused on cystic fibrosis and asthma drug development. From 2000-2003 he served in various business development roles with Diversa Corporation. In addition to his leadership role with Incisive Genetics, Dr. Chow concurrently serves as an Operating Partner with Accelerator Life Science Partners.
Dr. Chow holds B.Sc., M.Sc., and Ph.D. degrees in Microbiology and Immunology from the University of British Columbia in Vancouver, Canada.